Effect of dihydrocodeine tartrate tablets on pain degree of moderate and severe cancer pain
酒石酸双氢可待因片治疗中重度癌痛疼痛程度的影响

摘要

目的 分析探讨酒石酸双氢可待因片治疗中重度癌痛疼痛程度的影响效果。方法 选取我院2020年-2021年接受治疗患者且存在中重度癌痛患者120例为观察对象，所有患者均采用酒石酸双氢可待因片治疗，将患者治疗后的疼痛缓解率、不良反应发生率进行统计，并将治疗前后的生存质量进行比较。结果 120例患者中，完全缓解为53例，占44.2%，占比最多，总缓解率为100.0%；5例患者出现不良反应情况，占4.2%，患者症状较轻，经对症治疗后已痊愈；相较于治疗前，患者治疗后生存质量明显提升，存在显差异（P<0.05）。结论 采用酒石酸双氢可待因片治疗中重度癌痛患者能够有效降低疼痛程度，避免出现不良反应，获得较高的生存质量，临床疗效明显，值得在临床治疗中推广应用。

Abstract

Objective To analyze the effect of dihydrocodeine tartrate tablets in the treatment of moderate and severe cancer pain.
Methods 120 patients with moderate to severe cancer pain who were treated in our hospital from 2020 to 2021 were selected as the observation objects. All patients were treated with dihydrocodeine tartrate tablets. The pain relief rate and adverse reaction rate of patients after treatment were counted, and the quality of life before and after treatment were compared.
Results among the 120 patients, 53 patients had complete remission, accountting for 44.2%, accounting for the most, and the total remission rate was 100.0%; Five patients had adverse reactions, accounting for 4.2%. The patients had mild symptoms and recovered after symptomatic treatment; Compared with before treatment, the quality of life of patients after treatment was significantly improved (P<0.05).
Conclusion   dihydrocodeine tartrate tablets can effectively reduce the degree of pain, avoid adverse reactions, and obtain higher quality of life in patients with moderate and severe cancer pain. It has obvious clinical effect and is worth popularizing in clinical treatment.